Thermo Fisher Scientific Inc

• TMO Stock Price 24h change: +0.05%. From 618.72 USD to 619.01 USD. (Note: Intraday activity on Jan 22 showed opening at 637.39 USD, reflecting high volatility and a reach toward 52-week highs).
• From a technical perspective, the market presents a "strong bullish momentum": the stock is trading above its 50-day (588 USD) and 200-day (492 USD) moving averages. Indicators like the RSI (63.6) and MACD (3.32) suggest continued buying pressure, though some oscillators hint at "overbought" conditions near the 640 USD resistance level.
• Thermo Fisher announced strategic collaborations with NVIDIA and TetraScience to integrate advanced AI and interoperable data workflows into laboratory and biopharma R&D processes.
• The company unveiled a leadership transition plan where Marc N. Casper will become both Chairman and CEO effective March 1, 2026, aiming to streamline digital and infrastructure ambitions.
• Analysts at Zacks and other firms are closely monitoring TMO ahead of its upcoming earnings report next week, with expectations of a 5.6% year-over-year increase in EPS to 6.44 USD.
• Johnson & Johnson projected its 2026 revenue to reach 100 billion USD, driven by a surge in its cancer drug Darzalex, signaling strong demand within the broader life sciences and pharma sector.
• The NIH issued a new ban on the use of federal funds for research involving human fetal tissue from elective abortions, a policy shift that may impact certain long-term academic and clinical research workflows.

• TMO Stock Price 24h change: +0.05%. From 618.72 USD to 619.01 USD. The price remained stable as the market digested recent gains after reaching a 52-week high, supported by positive analyst sentiment and steady demand in the life sciences sector.
• From a technical perspective, TMO exhibits a "strongly bullish trend": the stock is trading above its 50-day ($586.39) and 200-day ($491.53) moving averages. While the RSI of 62.01 suggests it is approaching overbought territory, the MACD indicator remains in a buy zone, indicating sustained upward momentum despite short-term consolidation.
• Thermo Fisher announced a strategic collaboration with NVIDIA on January 12 to leverage AI for advancing laboratory automation and scientific instrumentation performance.
• Stifel Nicolaus raised its price target for TMO to $700 from $583 on January 9, maintaining a "Buy" rating based on improving macroeconomic conditions and strong execution.
• Zacks Research issued a positive forecast for TMO's upcoming Q4 earnings, highlighting the company's resilience in the biopharma channel despite global spending constraints.
• The U.S. biotech sector is projected to see a significant rebound in 2026, with a surge of $4.9 billion in capital raised in the first week of January alone, signaling renewed investor optimism.
• Industry reports for 2026 indicate a major shift toward AI-integrated R&D workflows, with 94% of life sciences leaders viewing AI as crucial for scalable operations and drug discovery efficiency.